Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00888615 · ClinicalTrials.gov registry record · Phase 2
Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase 2 study, sponsored by GOG Foundation.
- Completed
- Registry status
- Phase 2
- Development phase
- 58
- Enrollment target
NCT00888615 is a Phase 2 study that has completed, run by GOG Foundation. The registered enrollment target is 58 participants.
The verdict
NCT00888615, a Phase 2 study, has completed, sponsored by GOG Foundation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 58 participants
- Enrollment target
Study Summary
This phase II trial studies how well elesclomol sodium and paclitaxel work in treating patients with ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer that has returned after a period of improvement (recurrent) or is persistent. Drugs used in chemotherapy, such as elesclomol sodium and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Elesclomol sodium may also help paclitaxel work better by making tumor cells more sensitive to the drug.
Interventions
- DRUG Paclitaxel
- DRUG Elesclomol Sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2010-12-13 |
| Est. Completion | 2016-08-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00888615
The ClinicalTrials.gov registry entry for NCT00888615 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GOG Foundation, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Paclitaxel is the first listed.
NCT00888615 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00888615 about?
NCT00888615 is a clinical study titled "Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer". This phase II trial studies how well elesclomol sodium and paclitaxel work in treating patients with ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer that has returned after a period of improvement (recurrent) or is persistent. Drugs used in chemotherapy, such as elescl...
What is the current status of trial NCT00888615?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 58 participants. The study started on 2010-12-13. Estimated completion is 2016-08-31.
What interventions are being tested in trial NCT00888615?
The interventions under investigation include: Paclitaxel (DRUG), Elesclomol Sodium (DRUG).
Who is sponsoring clinical trial NCT00888615?
This trial is sponsored by GOG Foundation, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.